DE69841711D1 - Modulator der menschlichen mastzellaktivierung - Google Patents

Modulator der menschlichen mastzellaktivierung

Info

Publication number
DE69841711D1
DE69841711D1 DE69841711T DE69841711T DE69841711D1 DE 69841711 D1 DE69841711 D1 DE 69841711D1 DE 69841711 T DE69841711 T DE 69841711T DE 69841711 T DE69841711 T DE 69841711T DE 69841711 D1 DE69841711 D1 DE 69841711D1
Authority
DE
Germany
Prior art keywords
mast cell
purinoceptors
human
activation
atp binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841711T
Other languages
German (de)
English (en)
Inventor
Amir Pelleg
Edward B Schulman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duska Scientific Co
Original Assignee
Duska Scientific Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duska Scientific Co filed Critical Duska Scientific Co
Application granted granted Critical
Publication of DE69841711D1 publication Critical patent/DE69841711D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
DE69841711T 1997-03-25 1998-03-24 Modulator der menschlichen mastzellaktivierung Expired - Lifetime DE69841711D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4146197P 1997-03-25 1997-03-25
PCT/US1998/005922 WO1998042353A1 (en) 1997-03-25 1998-03-24 Modulation of human mast cell activation

Publications (1)

Publication Number Publication Date
DE69841711D1 true DE69841711D1 (de) 2010-07-22

Family

ID=21916643

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69841711T Expired - Lifetime DE69841711D1 (de) 1997-03-25 1998-03-24 Modulator der menschlichen mastzellaktivierung

Country Status (9)

Country Link
US (2) US6372724B1 (cg-RX-API-DMAC7.html)
EP (1) EP1011686B9 (cg-RX-API-DMAC7.html)
JP (1) JP2001518118A (cg-RX-API-DMAC7.html)
AT (1) ATE470441T1 (cg-RX-API-DMAC7.html)
AU (1) AU741713B2 (cg-RX-API-DMAC7.html)
CA (1) CA2288821C (cg-RX-API-DMAC7.html)
DE (1) DE69841711D1 (cg-RX-API-DMAC7.html)
DK (1) DK1011686T3 (cg-RX-API-DMAC7.html)
WO (1) WO1998042353A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2288821C (en) * 1997-03-25 2008-10-14 Allegheny University Of The Health Sciences Modulation of human mast cell activation
DK1187617T3 (da) * 1999-06-18 2004-04-13 Alcon Mfg Ltd Fremgangsmåde til at vælge koncentrationen af et amfipatisk antihistaminlægemiddel ved at bestemme lægemidlets overfladeaktivitetsmåltal
GB9916757D0 (en) 1999-07-17 1999-09-15 Glaxo Group Ltd Method
EP1269198A2 (en) * 2000-03-23 2003-01-02 Novartis AG Identification of mast/basophil activation inhibitors
US20040072865A1 (en) * 2001-01-15 2004-04-15 Bouillot Anne Marie Jeanne Aryl piperidine derivatives as inducers of ldl-receptor expression
JP2004520347A (ja) * 2001-01-15 2004-07-08 グラクソ グループ リミテッド Ldl−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
EP1351937A1 (en) * 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
MXPA04004215A (es) * 2001-11-06 2004-07-08 Inspire Pharmaceuticals Inc Metodo para el tratamiento o la prevencion de enfermedades inflamatorias.
WO2003070902A2 (en) * 2002-02-20 2003-08-28 Incyte Corporation Receptors and membrane-associated proteins
US20070276126A1 (en) * 2002-08-13 2007-11-29 Incyte Corporation Cell adhesion and extracellular matrix proteins
US20070219353A1 (en) * 2002-09-03 2007-09-20 Incyte Corporation Immune Response Associated Proteins
AU2003279829A1 (en) * 2002-10-04 2004-05-04 Incyte Corp Protein modification and maintenance molecules
AU2003300785A1 (en) * 2002-11-12 2004-06-03 Incyte Corporation Carbohydrate-associated proteins
AU2003295462A1 (en) * 2002-11-13 2004-06-03 Incyte Corporation Lipid-associated proteins
AU2003302234A1 (en) * 2002-11-26 2004-06-18 Incyte Corporation Immune response associated proteins
WO2004098539A2 (en) 2003-04-30 2004-11-18 Incyte Corporation Kinases and phosphatases
WO2006012639A2 (en) * 2004-07-22 2006-02-02 Duska Scientific Co. Method of diagnosing, monitoring and treating pulmonary diseases
EP1910535B1 (en) 2005-06-24 2016-08-17 The Walter And Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
CA2680801A1 (en) * 2007-03-14 2008-09-18 Sierra Molecular Corporation Compositions, systems, and methods for preservation and/or stabilizationof a cell and/or macromolecule
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
US10107795B2 (en) 2012-10-25 2018-10-23 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for the prevention and treatment of diet-induced obesity
US10614684B2 (en) 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53148539A (en) * 1977-05-30 1978-12-25 Fujisawa Pharmaceut Co Ltd Antiallergic agnet
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
EP0760850A1 (en) * 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5874420A (en) 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
CA2288821C (en) * 1997-03-25 2008-10-14 Allegheny University Of The Health Sciences Modulation of human mast cell activation

Also Published As

Publication number Publication date
ATE470441T1 (de) 2010-06-15
WO1998042353A1 (en) 1998-10-01
US6465441B2 (en) 2002-10-15
US6372724B1 (en) 2002-04-16
EP1011686B9 (en) 2011-02-09
EP1011686B1 (en) 2010-06-09
JP2001518118A (ja) 2001-10-09
EP1011686A4 (en) 2003-03-19
CA2288821A1 (en) 1998-10-01
AU7098598A (en) 1998-10-20
AU741713B2 (en) 2001-12-06
DK1011686T3 (da) 2010-10-11
US20020055515A1 (en) 2002-05-09
CA2288821C (en) 2008-10-14
EP1011686A1 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
ATE470441T1 (de) Modulator der menschlichen mastzellaktivierung
ATE510551T1 (de) Hemmung von gs-fdh zur modulierung der no- bioaktivität
ATE347585T1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
DE69938923D1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
WO2002099075A3 (en) Prmts as modifiers of the p53 pathway and methods of use
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE50015700D1 (de) Substituierte indole zur modulierung von nfkb-aktivität
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
DE69620458D1 (de) Benzofuran-carboxamide und -sulfonamide
HUP0004544A2 (hu) Angiotenzin-átalakító enzim inhibitora és diuretikum kombinációjának alkalmazása mikrokeringési rendellenességek kezelésére szolgáló gyógyászati készítmény előállítására
DE69835288D1 (de) Kombinationstherapie zur modulation der humanen sexualreaktion
BR0212070A (pt) ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica
ATE342062T1 (de) Angiotensin ii zur verbesserung der befruchtung
DK1185621T3 (da) Overflade til cellekultur
ES2039578T3 (es) Procedimiento para producir mercapto-acilaminoacidos antihipertensivos.
WO2004053144A3 (en) Modulation of stem cell differentiation by modulation of caspase-3 activity
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
WO2003049683A3 (en) Use of parapox b2l protein to treat cancer and modify immune responses
NZ515727A (en) Aminotetralin derivative for the therapy of cardiovascular diseases
ES2181160T3 (es) Derivados de 1,4-dihidropiridina y su utilizacion en terapia.
WO2004015072A3 (en) Mrbs as modifiers of the rb pathway and methods of use
WO2003052070A3 (en) Vps41s as modifiers of cell death and methods of use